HSP90B1 and neoplasm: To demonstrate the ability of gp96 to prime tumor-specific immunity, BALB/c mice were immunized with 1 μg of K7M2-gp96 (or normal tissue–derived, n-gp96) twice as shown in Figure 5B’s schema, then challenged with syngeneic K7M2 tumor 1 week later.